MX2020007429A - Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). - Google Patents

Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).

Info

Publication number
MX2020007429A
MX2020007429A MX2020007429A MX2020007429A MX2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A MX 2020007429 A MX2020007429 A MX 2020007429A
Authority
MX
Mexico
Prior art keywords
antibodies
subcutaneous dosing
disclosed
methods
diseases
Prior art date
Application number
MX2020007429A
Other languages
English (en)
Inventor
Robert Evans
Martin Dahl
Eric Fedyk
Lin Zhao
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020007429A publication Critical patent/MX2020007429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen métodos para administrar anticuerpos anti-CD38 aislados a dosis bajas por vía subcutánea. Los métodos proporcionan un tratamiento eficaz para enfermedades autoinmunitarias y tipos de cáncer, incluso enfermedades hematológicas. También se describen formas de dosis unitaria para los anticuerpos anti-CD38.
MX2020007429A 2018-01-12 2019-01-14 Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). MX2020007429A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862617146P 2018-01-12 2018-01-12
PCT/US2019/013547 WO2019140410A1 (en) 2018-01-12 2019-01-14 Subcutaneous dosing of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
MX2020007429A true MX2020007429A (es) 2020-10-15

Family

ID=65529766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007429A MX2020007429A (es) 2018-01-12 2019-01-14 Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).

Country Status (11)

Country Link
US (1) US20210388103A1 (es)
EP (1) EP3737702A1 (es)
JP (2) JP2021510737A (es)
KR (1) KR20210006321A (es)
CN (1) CN112739715A (es)
AU (1) AU2019208102A1 (es)
BR (1) BR112020014052A2 (es)
CA (1) CA3088199A1 (es)
CO (1) CO2020008561A2 (es)
MX (1) MX2020007429A (es)
WO (1) WO2019140410A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ATE489395T1 (de) 2000-12-12 2010-12-15 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
JP4166691B2 (ja) 2001-08-03 2008-10-15 タイコ ヘルスケア グループ エルピー 組織マーキング装置および方法
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses

Also Published As

Publication number Publication date
WO2019140410A1 (en) 2019-07-18
AU2019208102A1 (en) 2020-07-02
RU2020126723A3 (es) 2022-02-14
KR20210006321A (ko) 2021-01-18
EP3737702A1 (en) 2020-11-18
US20210388103A1 (en) 2021-12-16
JP2021510737A (ja) 2021-04-30
CA3088199A1 (en) 2019-07-18
CO2020008561A2 (es) 2020-10-30
RU2020126723A (ru) 2022-02-14
JP2024023247A (ja) 2024-02-21
CN112739715A (zh) 2021-04-30
BR112020014052A2 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
MX2020010144A (es) Dosificación subcutánea de anticuerpos anti grupo de diferenciación 38 (cd38).
MX2020010458A (es) Conjugados de camptotecina-peptido.
MX2019012462A (es) Terapia combinada.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
MX2021002764A (es) Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores.
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
MX2022003930A (es) Conjugados de péptido de camptotecina.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2017014977A (es) Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
TN2018000021A1 (en) ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
MX2022003306A (es) Inmunocitoquina que comprende un complejo de proteina heterodimerico basado en il-15/il-15ra y su uso.
WO2020132658A3 (en) Tubulysins and protein-tubulysin conjugates
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
MX2019006131A (es) Metodos para tratar cancer de mama positivo para prlr.
MX2020007429A (es) Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
AU2017408066A1 (en) Novel treatment of mitochondrial diseases